Home » Newsletters » BioWorld Science

BioWorld Science

June 10, 1998

View Archived Issues

Ergo Science meets with FDA regarding Ergoset

Digene awarded SBIR grant for HSV test development

Scriptgen and Lilly expand drug discovery collaboration

Anesta signs Actiq partnership with Lafon

Clinical trial results for DUROS leuprolide implant announced at AUA meeting

Immunex's CD40 Ligand enters phase I

Affymetrix and Human Genome Sciences to develop bacterial GeneChip probe arrays

Novopharm Biotech completes patient enrollment for GPI-2A phase Ia trial

Clarithromycin licensed to Boehringer Ingelheim for Latin America

Ixion receives notice of allowance for bacterial detection technology

Demeter BioTechnologies awarded U.S. patent for peptide technology

Magainin: Q1 1998 highlights

Ribi ImmunoChem: Q1 1998 highlights

GlycoDesign starts phase II trial of GD0039 for the treatment of RCC

New and established treatments for BPH reviewed at AUA

Controlled trial of rhGH in patients with dilated cardiomyopathy and chronic heart failure

Ribozyme obtains license to sickle cell anemia treatment technology

Ibutilide compared to other antiarrhythmic agents for effects on typical atrial flutter

Rosiglitazone and troglitazone exert differential effects on small arteries in vitro

U.S. patent issued covering aerosolized gene delivery using cationic lipids

Miravant and Xillix Technologies enter early-stage cancer collaboration

AHP reports dopamine autoreceptor agonists with antipsychotic potential

Crambescidin 816, an antiviral and antitumor agent from a marine sponge

DVT imaging agent enters phase II in Canada

Latanoprost compared to unoprostone in monkeys with glaucoma

Fuisz and Boehringer Ingelheim agreement for CEFORM EA technology

Alpha-Beta Technology receives grants for antifungal drug discovery

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...